OS Therapies announced it will present 2.5-year overall survival data from its Phase 2b OST-HER2 trial for pulmonary metastatic osteosarcoma at the 2026 ASCO Annual Meeting. OST-HER2 is a gene-edited, listeria-based immunotherapy targeting HER2 mutations, designed to prevent or delay cancer recurrence after surgery. The therapy has received multiple FDA and EMA designations, including Orphan Drug and Fast Track, and the company aims to file for U.S. accelerated approval and conditional marketing authorizations in Europe and other regions in 2026. Positive earlier trial results showed significant benefits in event-free and overall survival, highlighting OST-HER2's potential as a new treatment for osteosarcoma.
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
BMW is recalling 29,119 plug-in hybrid sedans due to a potential fire risk caused by corrosion in the engine starter's electrical relay. This defect can lead to a short circuit and overheating even when the vehicle is parked with the ignition off. Th...
